Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE BRAF mutant and HER-2 positive mCRC will soon be provided with approved targeted treatments and check-point inhibitors demonstrated effectiveness in microsatellite instability (MSI) - high mCRC. 31786838

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE In multivariate analysis, histologic grade 3 (p = 0.014), presence of extracranial metastasis (p < 0.001), the number of BM (>4; p = 0.002), hormone receptor negativity (p = 0.005), HER2-negativity (p = 0.003), and shorter time interval (<30 months) between BC and BM diagnosis (p = 0.007) were associated with inferior OS. 31677532

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE High KANK1 protein expression was correlated with smaller tumour size and HER2 negativity, and better outcome in terms of longer breast cancer-specific survival [p = 0.013, HR 0.7, 95% CI 0.536-0.893] and time to distant metastasis [p = 0.033, HR 0.65, 95% CI 0.51-0.819]. 31679074

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE In the multivariate analysis, significant independent predictors in nonSLN metastasis development were found to be HER2 positivity, PNI, mSLN diameter ≥10,5 mm and ENE. 31519397

2020

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Ado-trastuzumab emtansine (T-DM1/Kadcyla<sup>®</sup>;Genentech) is an antibody-drug conjugate used in the treatment of human epidermal growth factor receptor-2-positive metastasized breast cancer. 30820718

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Patients with HER2 amplification showed shorter median times from disease discovery to LN metastasis (HER2 amplification vs HER2 non-amplification; 15.6 vs. 10.0 months; P=0.50) and from LN dissection to disease progression (HER2 amplification vs. HER2 non-amplification, 16.2 vs. 13.6 months; P=0.11). 30854041

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 AlteredExpression BEFREE HER2/ErbB2 activation turns on transcriptional processes that induce local invasion and lead to systemic metastasis. 30622337

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE We characterized the small molecule MBQ-167 as an effective dual Rac/Cdc42 inhibitor that reduces HER2-type tumor growth and metastasis in mice by ∼90%. 31720502

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Local recurrences (7.5%) and distant metastases (25.6%) occurred most often in HER2 positive disease and the least often in luminal A (3.7% and 9.5%, respectively). 30368776

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Increase in HER2 receptor protein due to gene amplification, results in aggressive growth, and high metastasis in cancer cells. 30398120

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 AlteredExpression BEFREE Human epidermal growth factor receptor 2 (HER2) is overexpressed in nearly 20-30% of breast cancers and is associated with metastasis resulting in poor patient survival and high recurrence. 31460159

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE It was shown that elevated TMED3 markedly correlated with ER, PR, Her-2 status, and lymph nodes metastases in addition to significant association with poor overall prognosis. 30976199

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Together, this study demonstrates that ATF4-ZEB1 is important for HER2-mediated cell migration and suggests that ATF4-ZEB1 may be potential therapeutic targets for breast cancer metastasis. 31064130

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 GeneticVariation BEFREE On the other hand, rs147574894 negatively correlated with histological type and grade, tumor size, Her2 positivity, molecular type, and ER+/Her2-, while rs148626207 correlated positively with histological grade, but negatively with distant metastasis and triple-negative status. 30027470

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE For metastasis studies, 7 patient-derived xenograft tumours (PDX: BB3RC32, ER+ PR+ HER2-; BB2RC08, ER+ PR+ ER2-; BB6RC37, ER- PR- HER2- and BB6RC39, ER+ PR+ HER2+), MDA-MB-231-luc2, T47D-luc2 or MCF7-Luc2 cells were injected into the 4th mammary ducts and metastases monitored by luciferase imaging and confirmed on histological sections. 31783893

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE OBC patients were between SBC and mastectomy patients in terms of clinical and pathological tumour size (all p < 0.001), rates of lobular cancers (v.SBC:p = 0.015 and v.mastectomy:p < 0.001), high-grade tumours (v.SBC:p = 0.030 and v.mastectomy:p = 0.008), ER negative (v.SBC: p = 0.042) and HER-2 positive (v.SBC: p = 0.003) tumours, and nodal metastasis (v.mastectomy: p < 0.001). 30902354

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Multivariable ordinal logistic regression was used to investigate the association between T2D/insulin and breast cancer characteristics, including TNM classification (tumor size, lymph node status, metastasis), morphology, grade, estrogen receptor and progesterone receptor (PR), human epidermal growth factor receptor 2, and molecular subtype. 30679303

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE HER2 positivity in nonpleomorphic ILCs was associated with higher recurrence/metastasis with hazard ratio of 2.03 (P < .05). 31786600

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 AlteredExpression BEFREE The ErbB2 receptor tyrosine kinase is overexpressed in approximately 15-20% of breast tumors and associated with aggressive disease and poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration and proliferation in normal and pathological contexts. p130Cas overexpression in ErbB2 human breast cancer correlates with poor prognosis and metastasis formation. 30816273

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Because these genes are presumably expressed in populations of DTCs and many encode proteins that are known therapeutic targets (e.g., ERBB2), these results also suggest a potential approach for targeted DTC therapy to mitigate distant metastases in TNBC. 31432366

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 AlteredExpression BEFREE Among invasive-VPD, two clusters were found: the second with more frequent HER2/neu overexpression (67% vs. 0%) and nodal metastases (100% vs. 25%). 31297606

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 GeneticVariation BEFREE The ERBB2 mutation status was determined by next generation sequencing and/or pyrosequencing in n = 106 ILBCs, including n = 86 primary or locally recurrent tumors and n = 20 metastases from visceral organs, soft tissue, or skin. 30520184

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE In the subgroup of ERBB2-amplified breast cancers, a high p140Cap status predicts a significantly lower probability of developing a distant event and a clear difference in survival. p140Cap is causal in dampening ERBB2-positive tumor cell progression, impairing tumor onset and growth, and counteracting epithelial mesenchymal transition, resulting in decreased metastasis formation. 31681758

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Relative to HR+/HER2- subtype, local recurrence was greater in HER2+ metastases (HR 3.20, 95% CI 1.78-5.75, p < 0.001), while patients with TNBC demonstrated higher rates of new brain metastases after initial treatment (HR 3.16, 95% CI 1.99-5.02, p < 0.001) and shorter time to salvage whole brain radiation (WBRT) (HR 3.79, 95% CI 1.36-10.56, p = 0.01) and salvage stereotactic radiation (HR 1.86, 95% CI 1.11-3.10, p = 0.02). 30982195

2019

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.600 Biomarker BEFREE Trastuzumab resistance followed by metastasis is a major obstacle for improving the clinical outcome of patients with advanced human epidermal growth factor receptor 2-positive (HER-2+) breast cancer. 30621694

2019